Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 9, Issue 5  May 2013
http://www.landesbioscience.com/journals/vaccines/toc/volume/9/issue/5/

Commentary
Tolerogenic vaccines for Multiple sclerosis
Volume 9, Issue 5   May 2013
http://dx.doi.org/10.4161/hv.23685
Mark D. Mannie and Alan D. Curtis, II

Abstract:
Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.

http://www.landesbioscience.com/journals/vaccines/article/23685/